Constructing a Novel Signature Based on Immune-Related lncRNA to Improve Prognosis Prediction of Cervical Squamous Cell Carcinoma Patients

Researchers assessed the correlation between immune infiltration status, chemotherapeutics sensitivity, immune checkpoint proteins, and the signature.
[Reproductive Sciences]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Single-Cell Multi-Omics Reveals Dyssynchrony of the Innate and Adaptive Immune System in Progressive COVID-19

Investigators used multi-omics single-cell analysis to probe the dynamic immune responses in hospitalized patients with stable or progressive course of COVID-19, explore V(D)J repertoires, and assess the cellular effects of tocilizumab.
[Nature Communications]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Fewer LAG-3+ T Cells in Relapsing-Remitting Multiple Sclerosis and Type 1 Diabetes

The authors observed significantly fewer LAG-3+ CD4 and CD8 T cells from subjects with relapsing-remitting multiple sclerosis and type 1 diabetes.
[Journal of Immunology]
[zotpress userid=” items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Nanjing Leads Biolabs and BeiGene Announce Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody; BeiGene Granted Exclusive Commercialization Rights Outside of China

BeiGene announced entry into a license and collaboration agreement granting BeiGene worldwide research, development and manufacturing rights and exclusive commercialization rights outside of China to LBL-007, a novel investigational antibody targeting the LAG-3 pathway.
[BeiGene]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Oncolytic Adenovirus Inhibits Malignant Ascites of Advanced Ovarian Cancer via Reprograming Ascitic Immune Microenvironment

Scientists found that oncolytic adenovirus conferred an effective ability to reduce ascites development and prolong overall survival.
[Molecular Therapy-Oncolytics]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractPress ReleaseGraphical Abstract
Bookmark

No account yet? Register

Share

Engineered Small Extracellular Vesicles as a FGL1/PD-L1 Dual-Targeting Delivery System for Alleviating Immune Rejection

Among various cell sources, FGL1/PD-L1 small extracellular vesicles (sEVs) derived from MSCs not only enriched FGL1/PD-L1 expression but also maintained the immunomodulatory properties of unmodified MSC sEVs.
[Advanced Science]
[zotpress userid=’7992332′ items=’EEEEEEEE’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Galecto Announces Clinical Collaboration with Roche for Phase II Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer

Galecto, Inc. announced that it has entered into a clinical trial supply agreement with Roche to explore the combination of GB1211, Galecto’s oral galectin-3 inhibitor, with Roche’s PD-L1 checkpoint inhibitor atezolizumab in Galecto’s planned Phase IIa trial in non-small-cell lung cancer
[Galecto, Inc.]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III

Immutep Limited announced it has received positive feedback from the European Medicines Agency regarding its clinical development program for lead product candidate, eftilagimod alpha, including the planned Phase III trial in MBC.
[Immutep Limited]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

European Medicines Agency Validates Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma

Bristol Myers Squibb announced Marketing Authorization Application (MAA) validation for the LAG-3-blocking antibody relatlimab and nivolumab fixed-dose combination for first-line treatment of adult and pediatric patients with advanced (unresectable or metastatic) melanoma.
[Bristol Myers Squibb]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Polymorphic Estrogen Receptor Binding Site Causes Cd2-Dependent Sex Bias in the Susceptibility to Autoimmune Diseases

Scientists positionally identified a polymorphic estrogen receptor binding site that regulated Cd2 expression, leading to female-specific differences in T cell-dependent mouse models of autoimmunity.
[Nature Communications]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

US Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

Bristol Myers Squibb announced that the US FDA has accepted for priority review the Biologics License Application for the LAG-3-blocking antibody relatlimab and nivolumab fixed-dose combination, administered as a single infusion, for the treatment of adult and pediatric patients with unresectable or metastatic melanoma.
[Bristol Myers Squibb]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share
Share